Terms: = Thyroid cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346
58 results:
1. Endometrial cytological findings for a mesonephric-like endometrial adenocarcinoma: A case report.
Omine H; Ishida K; Sasaki N; Kato H; Nagai T; Ishikawa M; Takaoka M; Noda S; Matsuda H; Mitsuhashi A
Diagn Cytopathol; 2024 Jun; 52(6):E129-E133. PubMed ID: 38454318
[TBL] [Abstract] [Full Text] [Related]
2. Fine needle aspiration biopsy of parathyroid; is it meaningful? A cytologic study of 81 cases with histological and clinical correlations.
Bakuła-Zalewska E; Długosińska J; Stanek-Widera A; Góralski P; Gałczyński J; Żyłka A; Durzyńska M; Dedecjus M
Cytopathology; 2024 May; 35(3):362-370. PubMed ID: 38213192
[TBL] [Abstract] [Full Text] [Related]
3. Liver Mass as First-Time Diagnosis of Sarcomatoid Anaplastic thyroid Carcinoma: A Rare Malignancy Presenting at an Unexpected Body Site.
Kamashki A; Rivera M; Sturgis CD
Am J Case Rep; 2023 Dec; 24():e941838. PubMed ID: 38041397
[TBL] [Abstract] [Full Text] [Related]
4. Divergent Lineage Markers in Anaplastic thyroid Carcinoma.
Mneimneh WS; Asa SL
Am J Surg Pathol; 2024 Feb; 48(2):230-237. PubMed ID: 37972932
[TBL] [Abstract] [Full Text] [Related]
5. Immunoreactivity of TTF-1, GATA-3, CEA, and p16/Ki67 cocktail in Cellprep®-processed control samples: Comparison of long-term storage in vials and slides.
Ryu A; Honma K; Umeno Y; Uefuji F; Muramatsu T; Nishimura S; Tanada S; Yamamoto T; Nagata S; Yamasaki T; Ohue M
Diagn Cytopathol; 2024 Jan; 52(1):3-9. PubMed ID: 37740615
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma.
Lee Y; Choi S; Kim HS
Int J Gynecol Pathol; 2024 May; 43(3):221-232. PubMed ID: 37566876
[TBL] [Abstract] [Full Text] [Related]
7. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
[TBL] [Abstract] [Full Text] [Related]
8. Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy.
Doudoo CO; Gyekye PK; Emi-Reynolds G; Adu S; Kpeglo DO; Nii Adu Tagoe S; Agyiri K
J Med Imaging Radiat Sci; 2023 Jun; 54(2):335-342. PubMed ID: 37087327
[TBL] [Abstract] [Full Text] [Related]
9. Unraveling the significance of TSHR mutations in indeterminate thyroid cytology specimens.
Andrianus S; Gubbiotti MA; Mandel SJ; Nikiforov YE; Baloch Z
Diagn Cytopathol; 2023 Jul; 51(7):406-413. PubMed ID: 37042127
[TBL] [Abstract] [Full Text] [Related]
10. Mesonephric-like adenocarcinoma of the ovary with squamoid morular metaplasia, aberrant β-catenin expression, and concurrent FGFR2 and CTNNB1 mutations: a case report.
Xu J; Park KJ; Rehrauer WM; Weisman PS
Virchows Arch; 2024 Jan; 484(1):147-150. PubMed ID: 36856760
[TBL] [Abstract] [Full Text] [Related]
11. Urothelial carcinoma metastases impacting the CNS: A 20-year retrospective series.
Guzman SJ; Kleinschmidt-DeMasters BK
Ann Diagn Pathol; 2023 Jun; 64():152109. PubMed ID: 36822051
[TBL] [Abstract] [Full Text] [Related]
12. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Androgen Receptor-Positive TNBC.
Guo Q; Qiu P; Yao Q; Chen J; Lin J
Dis Markers; 2022; 2022():4964793. PubMed ID: 36157217
[TBL] [Abstract] [Full Text] [Related]
13. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall.
Shen T; Zhao J; Zhao M; Taggart MW; Ramalingam P; Gong Y; Wu Y; Liu H; Zhang J; Resetkova E; Wang WL; Ding Q; Huo L; Yoon E
Hum Pathol; 2022 Jul; 125():35-47. PubMed ID: 35417734
[TBL] [Abstract] [Full Text] [Related]
14. A Population-Based Analysis of Outpatient thyroidectomy: Safe and Under-Utilized.
Noel CW; Griffiths R; Siu J; Forner D; Urbach D; Freeman J; Goldstein DP; Irish JC; Higgins KM; Devon K; Pasternak JD; Eskander A
Laryngoscope; 2021 Nov; 131(11):2625-2633. PubMed ID: 34378810
[TBL] [Abstract] [Full Text] [Related]
15. Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma.
Collins K; Alkashash AM; Hwang M; Kaimakliotis HZ; Cheng L; Idrees MT
Int J Surg Pathol; 2022 Apr; 30(2):207-213. PubMed ID: 34255554
[TBL] [Abstract] [Full Text] [Related]
16. The diagnostic utility of INSM1 and gata3 in discriminating problematic medullary thyroid carcinoma, thyroid and parathyroid lesions.
Adel Hakim S; Mohamed Abd Raboh N
Pol J Pathol; 2021; 72(1):11-22. PubMed ID: 34060284
[TBL] [Abstract] [Full Text] [Related]
17. Monoclonal/polyclonal PAX-8, PTH and gata3 immunohistochemistry in parathyroid lesions.
Altınay S; Erözgür B; Dural AC; Volante M; Papotti MG
J Endocrinol Invest; 2021 Sep; 44(9):1997-2008. PubMed ID: 33566340
[TBL] [Abstract] [Full Text] [Related]
18. Dose reduction in hdr brachytherapy of esophageal cancer using gold and gold alloy plaques: a Monte Carlo study.
Masoudi SF; Baratian S; Asadi S; Rasouli FS
Radiat Environ Biophys; 2021 Mar; 60(1):115-124. PubMed ID: 33389051
[TBL] [Abstract] [Full Text] [Related]
19. Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6-NTRK3 fusion in both components.
Xu J; Weisman P
Genes Chromosomes Cancer; 2021 Jun; 60(6):447-451. PubMed ID: 33342011
[TBL] [Abstract] [Full Text] [Related]
20. Parathyroid carcinoma with sarcomatoid differentiation: a case report and literature review.
Hu L; Xie X
Diagn Pathol; 2020 Dec; 15(1):142. PubMed ID: 33317559
[TBL] [Abstract] [Full Text] [Related]
[Next]
